VALN - Pfizer Valneva Lyme disease vaccine shows response in kids over 5 in phase 2 trial

Pfizer (NYSE:PFE) Valneva (NASDAQ:VALN) said they plan to include children above 5 years of age in a planned phase 3 trial of their Lyme disease vaccine VLA15 after positive pediatric data was reported from a phase 2 trial, which included children aged 5 years to 17 years, among others. The study compared the immunogenicity and safety of VLA15 after administration of two (at months 0 and 6) or three (at months 0, 2 and 6) primary series doses in groups aged 5-11 years, 12-17 years and 18-65 years. The companies said that in children 5 years to 17 years who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested. The companies had reported data for people 18 years to 65 years old in February. The companies added that like in adults, the immunogenicity and safety data

For further details see:

Pfizer, Valneva Lyme disease vaccine shows response in kids over 5 in phase 2 trial